Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/ACI.0000000000000108 http://scihub22266oqcxt.onion/10.1097/ACI.0000000000000108 C4374802!4374802!25159182     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Allergy+Clin+Immunol 2014 ; 14 (6): 570-5 Nephropedia Template TP {{tp|p=25159182|t=2014. Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes |pdf=|usr=}}{{25159182}} gab.com Text Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes JO: Curr Opin Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=25159182 #FOAvip Purpose of review: To summarize recent advances in interleukin (IL)-4 and IL-13 blockade in the treatment of asthma. Recent findings: Historically, anti-cytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of asthma. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients has led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anti-cytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials both types of therapies have demonstrated therapeutic benefit. Summary: Anti-IL-4/13 therapies, guided by knowledge of an individuals? underlying pathophysiology, are a promising class of therapies for treatment of asthma. Twit Text FOAVip Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes ????Curr Opin Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=25159182 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25159182 #FOAvip English Wikipedia <ref>{{Cite pmid|25159182}}</ref> Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes #MMPMID25159182 Kau AL; Korenblat PE Curr Opin Allergy Clin Immunol 2014[Dec]; 14 (6): 570-5 PMID25159182show ga Purpose of review: To summarize recent advances in interleukin (IL)-4 and IL-13 blockade in the treatment of asthma. Recent findings: Historically, anti-cytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of asthma. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients has led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anti-cytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials both types of therapies have demonstrated therapeutic benefit. Summary: Anti-IL-4/13 therapies, guided by knowledge of an individuals? underlying pathophysiology, are a promising class of therapies for treatment of asthma. äAnti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes(epmc).pdf DeepDyve Pubget Overpricing